Bioretec Names Sarah van Hellenberg Hubar-Fisher as CEO to Drive Global Growth in Absorbable Orthopedic Implants

Tampere, Finland, August 27, 2025 (PRNewswire) -- Bioretec Ltd. has appointed Sarah van Hellenberg Hubar-Fisher as Chief Executive Officer, following her tenure as interim CEO since May 2025 and Board member since 2021. With more than 23 years of leadership in healthcare and medtech, including senior roles at Johnson & Johnson and venture capital firms Nina Capital and Growth Science Ventures, she brings extensive expertise in scaling innovative technologies. Her priorities include accelerating the global launch of RemeOs™, building on Activa®’s success, and expanding Bioretec’s position as a leader in absorbable orthopedic implants.

Read full article here.